Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 5/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 2/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1985069 | 0.97 | CNR1 (0.42) | CNR1CNR2KCNA5KCNH2HRH3 | |
| SCHEMBL1987339 | 0.94 | CNR1 (0.41) | CNR1CNR2KCNH2DRD2HTR1A | |
| SCHEMBL1128022 | 0.93 | CNR1 (0.40) | CNR1CNR2HTR1A | |
| SCHEMBL1127694 | 0.91 | CNR1 (0.40) | CNR1CNR2KCNH2HRH3DRD2 | |
| SCHEMBL12602474 | 0.91 | CNR1 (0.35) | CNR1CNR2KCNH2HRH3DRD2 | |
| SCHEMBL14723965 | 0.90 | CNR1 (0.35) | CNR1CNR2KCNH2HRH3DRD2 | |
| SCHEMBL1987361 | 0.90 | CNR1 (0.40) | CNR1CNR2HTR1A | |
| SCHEMBL1985030 | 0.87 | CNR1 (0.41) | CNR1CNR2KCNH2HTR1A | |
| SCHEMBL1988692 | 0.86 | CNR1 (0.46) | CNR1CNR2HTR1A | |
| SCHEMBL1990962 | 0.86 | CNR1 (0.42) | CNR1CNR2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383666-B2 | Pyrrole derivatives, preparation of same and therapeutic application thereof | SANOFI (FR) | 2013-02-26 | — | — | US | disclosed |
| US-8383666-B2 | Pyrrole derivatives, preparation of same and therapeutic application thereof | SANOFI (FR) | 2013-02-26 | — | — | US | disclosed |
| EP-2283008-B1 | PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2011-11-02 | — | — | EP | disclosed |
| EP-2283008-B1 | PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2011-11-02 | — | — | EP | disclosed |
| US-20110144157-A1 | PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
| US-20110144157-A1 | PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
| EP-2283008-A2 | PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF | Sanofi-aventis (FR) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009141533-A2 | PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009141533-A2 | PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144157-A1 | PYRROLE DERIVATIVES, PREPARATION OF SAME AND THERAPEUTIC APPLICATION THEREOF | ARG2, PYCR1, ARG1 | CNR1 548/4885CNR2 883/4885KCNA5 2575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.